- Home
- News
- latamerica
- coagulation factor
Coagulation Factor Articles & Analysis
5 news found
It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...
ByBayer AG
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. ...
Factor XI is a protein in the blood which is converted into its active enzyme form (Factor XIa) as part of the blood coagulation cascade. Factor XI is a promising and differentiated target for the development of safer anticoagulants because of its critical role in pathological versus normal thrombus formation uncoupling ...
ByBayer AG
A comprehensive summary of ASC618 preclinical development and dose translation approach will be presented in a poster: “Pharmacology, Toxicology and Safety Studies of ASC618, a Second-Generation Factor VIII Gene Therapy for Hemophilia A Development” on Tuesday, May 17 (Hall D, Poster Board Number: Tu-288, 5:30 PM – 6:30 PM ET, abstract number: 783). ...
FDA Orphan Drug Designation in 2020 for ASC618, these regulatory achievements will significantly facilitate the scientific and clinical development of ASC 618’s gene replacement therapies for hemophilia A, reflecting: A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement ...